Indivior PLC — Cyborg Score 7/10

Strategic Profile

The company completed Phase I of its transformation by growing U.S. SUBLOCADE net revenue, simplifying the organization and achieving expected annual non-GAAP operating expense savings of at least $150 million. Phase II, launched January 1, 2026, focuses on accelerating U.S. SUBLOCADE dispense unit growth and net revenue while immediately accelerating adjusted EBITDA and cash flow.

Cyborg Score Rationale

The company expects to grow SUBLOCADE net revenue by 11% while growing adjusted EBITDA by 35% and adjusted EBITDA margin by 14 percentage points in 2026. Recent strategic execution, operational efficiency gains, and strong guidance demonstrate solid positioning, though execution risk remains in a competitive OUD treatment market.

Top Insights

• Shifted domicile from UK to US effective January 26, 2026, signaling strategic realignment and potential tax/operational benefits
• Achieved S&P SmallCap 600 inclusion (December 2025), expanding institutional investor accessibility
• Resolved legacy DOJ obligations ($295M paid in full), eliminating significant litigation risk
• SUBLOCADE represents ~80% of projected 2026 revenue, indicating concentrated but proven revenue engine

Named Competitors

• Suboxone — Buprenorphine-naloxone combination for OUD treatment
• Methadone — Synthetic opioid agonist for opioid dependence maintenance
• Generic Buprenorphine — Cost-effective buprenorphine formulations

Recent Developments

• (January 2026) Announced 2026 guidance with 11% SUBLOCADE growth and 35% EBITDA growth expectations
• (January 2026) Completed domicile change from UK to US parent company structure
• (December 2025) Gained inclusion in S&P SmallCap 600 index
• (December 2025) Published clinical data showing extended-release buprenorphine efficacy in high-risk populations

Open the full interactive Indivior PLC report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.